As our industry continues to rapidly evolve, product diversity, world-class research and supply-chain advancements are becoming increasingly important. Our sharp focus on innovation at the global stage is accomplished through ongoing strategic investment and ownership of leading research, partnerships with disruptive brands and organizations, and acquisitions.

Canopy Health Innovations is a wholly-owned subsidiary of Canopy Growth Corporation. Canopy Health is a biopharmaceutical company focused on developing and researching clinically-ready, whole-plant cannabis drug formulations and dose delivery systems. The ultimate goal is to validate diversified treatment options for Canadians and for patients and consumers in other jurisdictions where treatment with cannabis is federally legal. The foundation of our research and development plan is to improve the quality of life and health of those suffering from acute and chronic illnesses. The proper formulation of cannabinoids means the opportunity to improve a number of common complaints and ailments, like pain, appetite stimulation, and sleep quality. Medical cannabis is also used to manage common diseases such as dementia, Alzheimer’s, autism, autoimmune diseases like Crohn’s disease and colitis, and fibromyalgia.

Canopy Animal Health is a wholly-owned subsidiary of Canopy Health, focused on creating cannabis-based healthcare products for companion animals. Our goal is to provide family pets with specialized cannabinoid medicines to maintain, improve, or extend their quality of life. Canopy Health has undertaken an extensive intellectual property review which forms the basis of all of our strategic plans.

Learn More

The Canopy Innovation Lab is supported by the Dealer’s License Area in Smiths Falls which allows the company to push product development and R&D beyond the limits of the Access to Cannabis for Medical Purposes Regulations. As new product types join the legally permissible framework, it’s always helpful to have a head start. Whether through in-house innovation or strategic partnerships, the Canopy Innovation Lab will play a pivotal role driving Canopy Growth’s aggressive innovation agenda.

Canopy Growth is a founding partner and owner of Entourage Phytolab, established to develop cannabis-based pharmaceutical products for the Brazilian and international markets. As part of the agreement, wholly-owned subsidiary Bedrocan Canada, Bedrocan International BV and local Brazilian partners created a new company called Bedrocan Brasil S.A, which will facilitate the importation of Bedrocan’s proprietary standardized cannabis varieties into the Brazilian market.

Apollo Applied Research is dedicated to identifying the most effective strains of medical cannabis for patients suffering with chronic pain as well as many other medical conditions. Apollo offers an evidence based approach to treating patients with medical cannabis by running two of Canada’s largest medical cannabis studies. Apollo’s continuing research helps better evaluate the benefits of medical cannabis and allows Apollo to discover and better understand the most effective strains for each condition. Apollo has been conducting clinical research on chronic pain since 2014 and in March of 2016 Apollo launched its newest study analyzing the effects of medical cannabis on patients with PTSD. Apollo’s research has been published in multiple medical journals and is regularly called upon to present at medical seminars and conferences including the Clinical Research Association of Canada.

Canopy Growth is an early investor in Scientus Pharma, a vertically-integrated biopharmaceutical Licensed Dealer focused on developing and commercializing pharmaceutical-grade cannabinoid derivative products. Scientus Pharma has the ability to wholesale, buy, process and sell cannabinoid derivatives, from and to Licensed Producers, as well as international markets. Canopy partially owns approximately 9.8% of Scientus Pharma.